Skip to main content
main-content

EASD 2019

55th EASD Annual Meeting coverage

Including news and expert commentaries on the VERIFY trial, DEFINE-HF trial, and PRIORITY study.

Featured

Expert interviews

20-09-2019 | Heart failure | Video | Article

Researcher comment: The DEFINE-HF trial

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

20-09-2019 | Nephropathy | Video | Article

Expert commentary: The PRIORITY trial

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

20-09-2019 | Insulin degludec | Video | Article

Researcher comment: The CONCLUDE trial

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).

19-09-2019 | Medications | Video | Article

Expert commentary: Trials of imeglimin in type 2 diabetes

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

19-09-2019 | Vildagliptin | Highlight | Article

Expert commentary: The VERIFY trial

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

19-09-2019 | Heart failure | Video | Article

Expert commentary: DAPA-HF and DEFINE-HF trials

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

19-09-2019 | Heart failure | Video | Article

Researcher comment: The DAPA-HF trial

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

More research news from EASD 2019

19-09-2019 | Continuous glucose monitoring | EASD 2019 | News

Majority of MDI users improve glycemic outcomes with CGM

Analysis of the GOLD study suggests that at least three-quarters of people with type 1 diabetes using multiple daily injections benefit from continuous glucose monitoring.

18-09-2019 | Pathophysiology | EASD 2019 | News

‘Strikingly different’ drivers of early type 2 diabetes onset in Asians, Europeans

The “classic” metabolic contributors to early-onset type 2 diabetes risk in European people explain little of the risk in Asian people, shows a comparison of Scottish and Asian Indian cohorts.

18-09-2019 | Pathogenesis | EASD 2019 | News

Type 2 diabetes genetic liability manifests in early lipid changes

Genetic liability to type 2 diabetes manifests in altered lipid profiles from as early as 8 years of age, say researchers.

EASD 2019 session recommendations

The Medicine Matters diabetes Editorial Board share their symposia picks and reactions from EASD 2019.

EASD 2019 clinical trial overviews

Get up to speed on the clinical trials headlining EASD 2019 with our brief overviews.

Image Credits